Association of Single-Nucleotide Polymorphisms in JAK3, STAT4, and STAT6 With New Cardiovascular Events in Incident Dialysis Patients

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 845-855

  Sperati, C John ^a   Parekh, Rulan S ^a,b,c   Berthier Schaad, Yvette ^b,d   Jaar, Bernard G ^a,b,c   Plantinga, Laura ^c   Fink, Nancy ^a,b   Powe, Neil R ^a,b,c   Smith, Michael W ^d   Coresh, Josef ^a,b,c   Kao, W H Linda ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cardiovascular diseases; Dialysis; genes; inflammation

Indexed keywords

ISOLEUCINE; JANUS KINASE 3; STAT4 PROTEIN; STAT6 PROTEIN; VALINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOGENESIS; RACE DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CARDIOVASCULAR DISEASES; DNA; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; INCIDENCE; JANUS KINASE 3; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; STAT4 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 64749107751     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.12.025     Document Type: Article

References (54)

1. US Renal Data System: USRDS 2008 Annual Data Report (2008), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
3. Kalantar-Zadeh K., Kovesdy C.P., Derose S.F., Horwich T.B., and Fonarow G.C. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 3 (2007) 493-506
4. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
5. Hansson G.K. Regulation of immune mechanisms in atherosclerosis. discussion 165-166. Ann N Y Acad Sci 947 (2001) 157-165
6. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581
7. Murray P.J. The JAK-STAT signaling pathway: Input and output integration. J Immunol 178 (2007) 2623-2629
8. Frostegard J., Ulfgren A.K., Nyberg P., et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145 (1999) 33-43
9. Huber S.A., Sakkinen P., David C., Newell M.K., and Tracy R.P. T Helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 103 (2001) 2610-2616
10. Benagiano M., Azzurri A., Ciervo A., et al. T Helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A 100 (2003) 6658-6663
11. Methe H., Brunner S., Wiegand D., Nabauer M., Koglin J., and Edelman E.R. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 45 (2005) 1939-1945
12. Hansson G.K., Holm J., and Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135 (1989) 169-175
13. Uyemura K., Demer L.L., Castle S.C., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97 (1996) 2130-2138
14. Lee T.S., Yen H.C., Pan C.C., and Chau L.Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19 (1999) 734-742
15. Laurat E., Poirier B., Tupin E., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104 (2001) 197-202
16. Davenport P., and Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163 (2003) 1117-1125
17. Galea P., Thibault G., Lacord M., Bardos P., and Lebranchu Y. IL-4, but not tumor necrosis factor-alpha, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway. J Immunol 151 (1993) 588-596
18. Kuhn H., Heydeck D., Hugou I., and Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 99 (1997) 888-893
19. Heydeck D., Thomas L., Schnurr K., et al. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: Evidence for the involvement of transcription factor STAT6. Blood 92 (1998) 2503-2510
20. Powe N.R., and Fink N.E. The CHOICE Study: A national study of dialysis outcomes in the United States. Nefrologia 19 suppl 1 (1999) S68-S72
21. SeattleSNPs: NHLBI Program for Genomic Applications, SeattleSNPs, Seattle, WA. http://pga.gs.washington.edu Accessed November 16, 2008
22. Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., and Nickerson D.A. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74 (2004) 106-120
23. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
24. Imamura K., McKinnon M., Middleton R., and Black N. Reliability of a comorbidity measure: The Index of Co-Existent Disease (ICED). J Clin Epidemiol 50 (1997) 1011-1016
25. Patterson N., Hattangadi N., Lane B., et al. Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74 (2004) 979-1000
26. Prentice R.L., Kalbfleisch J.D., Peterson Jr. A.V., Flournoy N., Farewell V.T., and Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 34 (1978) 541-554
27. Lunn M., and McNeil D. Applying cox regression to competing risks. Biometrics 51 (1995) 524-532
28. Riedy M.C., Dutra A.S., Blake T.B., et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics 37 (1996) 57-61
29. Saharinen P., and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277 (2002) 47954-47963
30. Walters D.K., Mercher T., Gu T.L., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 (2006) 65-75
31. Kawamura M., McVicar D.W., Johnston J.A., et al. Molecular cloning of L-JAK, a janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 91 (1994) 6374-6378
32. Chen M., Cheng A., Candotti F., et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 20 (2000) 947-956
33. O'Shea J.J., Husa M., Li D., et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 41 (2004) 727-737
34. Bruunsgaard H., Pedersen A.N., Schroll M., Skinhoj P., and Pedersen B.K. Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol 37 (2001) 127-136
35. Whitman S.C., Rateri D.L., Szilvassy S.J., Yokoyama W., and Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 24 (2004) 1049-1054
36. Nakai Y., Iwabuchi K., Fujii S., et al. Natural killer T cells accelerate atherogenesis in mice. Blood 104 (2004) 2051-2059
37. Mor A., Luboshits G., Planer D., Keren G., and George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 27 (2006) 2530-2537
38. + T cell differentiation is induced following activation in the absence of gamma-chain-dependent cytokine signals. J Immunol 176 (2006) 2059-2063
39. Taleb S., Tedgui A., and Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 263 (2008) 489-499
40. + regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 6 (2008) 987-997
41. Changelian P.S., Flanagan M.E., Ball D.J., et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 302 (2003) 875-878
42. Rousvoal G., Si M.S., Lau M., et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 19 (2006) 1014-1021
43. Conklyn M., Andresen C., Changelian P., and Kudlacz E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 76 (2004) 1248-1255
44. Paniagua R., Si M.S., Flores M.G., et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80 (2005) 1283-1292
45. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 85 (1999) e17-e24
46. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 2847-2853
47. Fichtlscherer S., Breuer S., Heeschen C., Dimmeler S., and Zeiher A.M. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 44-49
48. Balakrishnan V.S., Guo D., Rao M., et al. Cytokine gene polymorphisms in hemodialysis patients: Association with comorbidity, functionality, and serum albumin. Kidney Int 65 (2004) 1449-1460
49. Lee Y.W., Kuhn H., Hennig B., Neish A.S., and Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 33 (2001) 83-94
50. Lee Y.W., and Hirani A.A. Role of interleukin-4 in atherosclerosis. Arch Pharm Res 29 (2006) 1-15
51. Johnston J.A., Bacon C.M., Finbloom D.S., et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A 92 (1995) 8705-8709
52. Barry S.P., Townsend P.A., Latchman D.S., and Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 13 (2007) 82-89
53. Zhang L., Kao W.H., Berthier-Schaad Y., et al. Haplotype of signal transducer and activator of transcription 3 gene predicts cardiovascular disease in dialysis patients. J Am Soc Nephrol 17 (2006) 2285-2292
54. Balakrishnan V.S., and Rao M. Genetics and reverse epidemiology among patients on chronic hemodialysis. Semin Dial 20 (2007) 570-576